In fact, our findings suggest that the promotion of non-hyper-inflammatory NKG2A+ cells may achieve the desired goals of a sustained anti-tumor immune response: an orchestrated immune infiltration into the tumor and improved patient survival. Here, KLRC1 is linked to neoplasm.